Saying OrganiGram Holdings (NASDAQ:OGI) now has momentum following British American Tobacco‘s (NYSE:BTI) acquisition of almost 20% of the company, a pair of analysts see the marijuana grower’s market share doubling by 2026.
The increased opportunity also caused the analysts, Rahul Sarugaser and Michael W. Freeman at Raymond James (NYSE:RJF), to double their price target for its stock to $6 per share Canadian ($4.78).
The global cigarette giant paid $176 million for some 58 million shares of OrganiGram, representing a 19.9% stake. Together they will establish a center at the pot grower’s Moncton, New Brunswick, facility to develop new cannabis-based products.
The partnership also gives OrganiGram an opportunity to expand into the U.S. and new international markets, and it leaves open the possibility that British American could increase its ownership interest, perhaps even acquiring OrganiGram as the marijuana producer’s financials are markedly improved by the deal.
Sarugaser and Freeman are looking for OrganiGram’s revenue to significantly expand over the next few years, hitting almost $87 million this year, $92 million next year, and surging fivefold by 2025 to reach $584 million. That sort of acceleration should help OrganiGram’s share of the adult-use cannabis market in Canada to nearly double to 12.5% from its current 6.5%.
The analysts also maintained their outperform rating on the marijuana stock.
This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium advisory service. We’re motley! Questioning an investing thesis — even one of our own — helps us all think critically about investing and make decisions that help us become smarter, happier, and richer.
Need Your Help Today. Your $1 can change life.